JP2023021979A5 - - Google Patents

Download PDF

Info

Publication number
JP2023021979A5
JP2023021979A5 JP2022171607A JP2022171607A JP2023021979A5 JP 2023021979 A5 JP2023021979 A5 JP 2023021979A5 JP 2022171607 A JP2022171607 A JP 2022171607A JP 2022171607 A JP2022171607 A JP 2022171607A JP 2023021979 A5 JP2023021979 A5 JP 2023021979A5
Authority
JP
Japan
Prior art keywords
application
xml
entirety
hereby incorporated
sequence listing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022171607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023021979A (ja
Filing date
Publication date
Priority claimed from JP2018559673A external-priority patent/JP2019511562A/ja
Application filed filed Critical
Publication of JP2023021979A publication Critical patent/JP2023021979A/ja
Publication of JP2023021979A5 publication Critical patent/JP2023021979A5/ja
Pending legal-status Critical Current

Links

JP2022171607A 2016-02-01 2022-10-26 Rna媒介疾患を処置する化合物および方法 Pending JP2023021979A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662289671P 2016-02-01 2016-02-01
US62/289,671 2016-02-01
JP2018559673A JP2019511562A (ja) 2016-02-01 2017-02-01 Rna媒介疾患を処置する化合物および方法
JP2021087002A JP7167248B2 (ja) 2016-02-01 2021-05-24 Rna媒介疾患を処置する化合物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021087002A Division JP7167248B2 (ja) 2016-02-01 2021-05-24 Rna媒介疾患を処置する化合物および方法

Publications (2)

Publication Number Publication Date
JP2023021979A JP2023021979A (ja) 2023-02-14
JP2023021979A5 true JP2023021979A5 (https=) 2023-04-11

Family

ID=59499945

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559673A Pending JP2019511562A (ja) 2016-02-01 2017-02-01 Rna媒介疾患を処置する化合物および方法
JP2021087002A Active JP7167248B2 (ja) 2016-02-01 2021-05-24 Rna媒介疾患を処置する化合物および方法
JP2022171607A Pending JP2023021979A (ja) 2016-02-01 2022-10-26 Rna媒介疾患を処置する化合物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018559673A Pending JP2019511562A (ja) 2016-02-01 2017-02-01 Rna媒介疾患を処置する化合物および方法
JP2021087002A Active JP7167248B2 (ja) 2016-02-01 2021-05-24 Rna媒介疾患を処置する化合物および方法

Country Status (11)

Country Link
US (2) US20200115372A1 (https=)
EP (1) EP3411080A4 (https=)
JP (3) JP2019511562A (https=)
CN (2) CN108778345B (https=)
AU (1) AU2017215201B2 (https=)
CA (1) CA3012700A1 (https=)
IL (2) IL260859B (https=)
MX (1) MX2018009325A (https=)
RU (1) RU2018127537A (https=)
SG (1) SG11201806544XA (https=)
WO (1) WO2017136450A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523242A (ja) * 2016-07-01 2019-08-22 アラーキス セラピューティクス, インコーポレイテッド Rna機能をモジュレートするための化合物および方法
WO2018151810A1 (en) 2017-02-17 2018-08-23 The Scripps Research Institute Defining rna-small molecule affinity landscapes enables design of a small molecular inhibitor of an oncogenic non-coding rna
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2019109046A1 (en) * 2017-11-30 2019-06-06 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
WO2019236644A1 (en) * 2018-06-05 2019-12-12 Arrakis Therapeutics, Inc. Encoded libraries and methods of use for screening nucleic acid targets
CN109928933B (zh) * 2019-01-10 2021-02-26 安徽昊帆生物有限公司 2-氯-5-醛基嘧啶及其制备方法
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020167811A1 (en) * 2019-02-12 2020-08-20 The Scripps Research Institute A cross-linking approach to map small molecule-rna binding sites in cells
WO2020264572A1 (en) * 2019-06-27 2020-12-30 The Scripps Research Institute Fragment-based screening to identify small molecules that selectively bind rna
AU2020377204A1 (en) * 2019-11-01 2022-06-02 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
GB2591088B (en) * 2020-01-08 2024-07-03 Adv Med Solutions Ltd Antimicrobial fibres
JP2024542018A (ja) * 2021-10-28 2024-11-13 アラーキス セラピューティクス, インコーポレイテッド Rna分解剤およびその使用
CN114373522B (zh) * 2022-01-13 2024-09-27 腾讯科技(深圳)有限公司 分子生成模型的训练方法、装置、设备及存储介质
EP4463188A4 (en) * 2022-01-14 2025-10-22 Univ Leland Stanford Junior CHEMICALLY REVERSIBLE 2´-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION
JP2025539353A (ja) * 2022-11-23 2025-12-05 アラーキス セラピューティクス, インコーポレイテッド Rna分解剤およびその使用
CN115850907B (zh) * 2022-12-29 2024-12-17 福建泓光半导体材料有限公司 一种酚醛树脂组合物及其制备方法和应用以及固化浮雕图案的制备方法
CN119320798A (zh) * 2023-07-17 2025-01-17 中国科学院上海营养与健康研究所 一种可用于筛选针对rna重复序列药物的报告系统
WO2025024573A1 (en) * 2023-07-24 2025-01-30 Arrakis Therapeutics, Inc. Ccr4-not binding rna degraders
WO2025137537A1 (en) * 2023-12-22 2025-06-26 Arrakis Therapeutics, Inc. Compositions and methods for treating myc-mediated diseases
WO2025184391A1 (en) * 2024-02-27 2025-09-04 Arrakis Therapeutics, Inc. Covalent inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354363A (ja) * 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
US5514786A (en) * 1990-01-11 1996-05-07 Isis Pharmaceuticals, Inc. Compositions for inhibiting RNA activity
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
EP2591795B1 (en) * 2007-02-23 2018-02-28 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
MX381407B (es) * 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US10544090B2 (en) * 2012-07-10 2020-01-28 Georgia State University Research Foundation, Inc. Anthraquinone analogs and methods of making and using thereof
US9480752B2 (en) * 2012-07-10 2016-11-01 Baseclick Gmbh Anandamide-modified nucleic acid molecules
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
WO2016069922A1 (en) * 2014-10-29 2016-05-06 Biotium, Inc. Nucleic acid modifying agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2023021979A5 (https=)
JP2019502892A5 (https=)
JP2021524958A5 (https=)
CN112004801A (zh) 一种c-MET 抑制剂的晶型及其盐型和制备方法
CN111757878A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN110352605A (zh) 一种鉴权算法程序的添加方法、相关设备及系统
BRPI0515554A (pt) anticorpos anti-ox40l
JP2019514354A5 (https=)
JP2022518511A5 (https=)
JP2018520447A5 (https=)
CN110214154A (zh) 抗cd47抗体及其用途
CN111655682A (zh) 一种高活性sting蛋白激动剂化合物
JP2023502438A5 (https=)
JP2015512691A5 (https=)
JP2022521336A5 (https=)
JP2014520155A5 (https=)
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
JP2012504317A5 (https=)
WO2008001224A3 (en) Polypeptides from neisseria meningitidis
JP2014533241A5 (https=)
CN109715660A (zh) 一种能够特异性地结合il-17a的抗体及其功能片段
JP2022508630A5 (https=)
JP2021502362A5 (https=)
JP2019527311A5 (https=)
CN104941607A (zh) 用于清除血液中过量b2微球蛋白的苯乙烯系新结构吸附树脂